Abstract: An airflow diverter in a hard disk drive system. A top portion configured to couple with a top housing of the disk drive system. A thickness configured to create a top clearance between the diverter and a top actuator arm of the disk drive system wherein the top clearance approximates a bottom clearance between a bottom housing of the disk drive system and a bottom actuator arm of the disk drive system. At least one surface configured to divert the airflow in the disk drive system during the operation of the disk drive system.

Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

Abstract: A hard disk drive enclosure with conductive paths. A base plate comprising an electrically conductive material with at least one contact surface that allows for an electrically conductive path, wherein the at least one contact surface has a substantially flat surface. A cover comprising an electrically conductive material comprising at least one tab with a substantially flat surface for contacting the at least one contact surface of the base plate, wherein the at least one tab contacts the at least one contact surface of the base plate with a force and forms an electrically conductive path between the cover and the based plate, and wherein the at least one tab deforms upon the contact with the at least one contact surface of the base plate with the force.

Abstract: A Bernoulli Effect pick-up device (1) for the handling of products (20) comprises a surface (4) adapted such that gaseous fluid flow across said surface (4) provides a pick-up force to be generated, by the Bernoulli Effect, in a direction towards said surface (4), and a conduit (2) for the supply of the gaseous fluid. The conduit (2) has an outlet opening (5) at the surface (4) and is adapted to supply gaseous fluid in a direction opposed to the pick-up direction. The outlet (5) of the conduit (2) is associated with a deflector (9) for directing gaseous fluid across the surface (4) and preventing direct impingement of the fluid on a product (2) that has been picked-up by the device (1). The product (20) may for example be a slice of a foodstuff, e.g. tomato or hard-boiled egg.

Abstract: The disclosed technique enables a content provider to dynamically assemble content at the edge of the Internet, preferably on content delivery network (CDN) edge servers. Preferably, the content provider leverages an “edge side include” (ESI) markup language that is used to define Web page fragments for dynamic assembly at the edge. Dynamic assembly improves site performance by catching the objects that comprise dynamically generated pages at the edge of the Internet, close to the end user. The content provider designs and develops the business logic to form and assemble the pages, for example, by using the ESI language within its development environment. Instead of being assembled by an application/web server in a centralized data center, the application/web server sends a page template and content fragments to a CDN edge server where the page is assembled. Each content fragment can have its own cacheability profile to manage the “freshness” of the content.

Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Abstract: The present invention enables a content provider to dynamically assemble content at the edge of the Internet, preferably on content delivery network (CDN) edge servers. Preferably, the content provider leverages an “edge side include” (ESI) markup language that is used to define Web page fragments for dynamic assembly at the edge. Dynamic assembly improves site performance by catching the objects that comprise dynamically generated pages at the edge of the Internet, close to the end user. The content provider designs and develops the business logic to form and assemble the pages, for example, by using the ESI language within its development environment. Instead of being assembled by an application/web server in a centralized data center, the application/web server sends a page template and content fragments to a CDN edge server where the page is assembled. Each content fragment can have its own cacheability profile to manage the “freshness” of the content.

Abstract: In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting VEGF mRNA translation by orally administering said medicament once, twice or thrice daily to the subject.

Abstract: Polymer membranes are disclosed having increased permeability. The process of the present disclosure, for instance, can increase the ion permeability of membranes and/or the gas permeability of membranes. In one embodiment, for instance, a precursor polymer is subjected to energy in an amount sufficient to form damage tracks through the thickness of the polymer. The damage tracks are then oxidized to form free radical groups. The precursor polymer is then hydrolyzed causing ion groups to form that cluster along the damage tracks. In one embodiment, sulfonated tetrafluoroethylene-based copolymer ionomer membranes are formed that have increased conductivity. Other ionomer membranes that may be formed according to the present disclosure include copolymers of a vinyl hydrocarbon and a vinyl carboxylic acid.

Abstract: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

Abstract: Methods, systems and compositions for recovery of regenerant ions from spent regenerant solution by utilization of electrodialysis are provided. For example, in certain aspects methods for separating spent regenerant using an electrodialysis system comprising selective membranes are described. Furthermore, the invention provides methods for treating a friable solid ion-removal material to prevent fragmentation during regeneration.

Abstract: Disclosed herein is a method for manufacturing a feed thru for use in an electrolytic capacitor case. First, an electrode is inserted into a liquid injection mold. Liquid elastomer is then injected into the mold to surround a portion of the electrode. The elastomer is cured, and the resulting electrode and feed thru combination is inserted into a machined hole in a capacitor case. The machined hole may be located on either the base or the lid of the capacitor case. In other embodiments, a ferrule may also be placed in the liquid injection mold prior to injecting liquid elastomer. When a ferrule is used, the assembly may be welded into a machined hole in a capacitor case.

Abstract: A lifting apparatus for transporting a carbon based electrode having a threaded male end. The apparatus includes a casing having a top end and a bottom end. The casing defines an electrode aperture from the bottom end shaped to accept the threaded male end of the carbon based electrode to secure the lifting apparatus to the electrode. An attachment aperture is positioned in the top end while an attachment element is positioned in the attachment aperture and operatively engaging the top end of the casing. The attachment element is positioned to accept engagement from a crane or other powered lifting device, while the lifting apparatus is preferably manually attachable to the electrode.

Abstract: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing serum, plasma, and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Abstract: In accordance with the present invention, methods for inhibiting the translation of VEGF and methods for decreasing VEGF level by inhibiting VEGF translation are provided. In another aspect of the invention, compounds that inhibit the 5?-UTR-dependent translation of VEGF and methods for identifying such compounds are provided.